This study investigated the possible associations between the plasma levels of inflammatory markers, IL17A/F, and TLR4 and their connections with the degree of steatosis and hepatic fibrosis among patients with MASLD. This evidence concerns the gene IL17A and metabolic dysfunction-associated steatotic liver disease.